WHAT CAN WE KNOW FROM SELFIES- AN EXPLORATORY STUDY ONSELFIE AND THE IMPLICATION FOR MARKETERS

Jenny Weichen Ma,Yusheng Yang 글로벌지식마케팅경영학회 2016 Global Marketing Conference Vol.2016 No.7

Although “selfie” has become a social phenomenon, little is discussed in marketing literature regarding what marketers can actually learn from consumers using selfies. This study has collected cross-cultural data of a total of 396 selfie photos from Twitter and Sina Weibo, in order to provide empirical evidence that leads to a better understanding on selfies. The results emphasise the cross-cultural differences on taking selfies and how selfie as another form of consumers presenting the “ideal self” may influence what information marketers can obtain from consumer selfies. The limitations due to data collection methods are noted and implications for marketers are also discussed.

유수정체용 전방각지지렌즈 삽입 후 각막내피세포의 장기 변화

양재니,이진기,Jenny Yang,MD,Jin Ki Lee,MD,PhD 대한안과학회 2012 대한안과학회지 Vol.53 No.2

Purpose: To evaluate long-term endothelial cell changes in phakic eyes that underwent implantation of an angle-supported anterior chamber lens to correct myopia. Methods: A retrospective analysis was performed in 110 eyes of 55 patients who underwent implantation of angle-supported anterior chamber lenses with a follow-up period longer than 5 years. Comparisons were made between preoperative and postoperative endothelial cell density, coefficient of variation, and percentage of hexagonal cells. Results: Mean preoperative corneal endothelial cell density was 2951 ± 336 cells/mm2 and the percentage of cell loss was 3.8% at year 1, 12.6% at year 3, 13.4% at year 5, 22.5% at year 7, and 22.2% at year 9. Explantation was required in 13 eyes (11.8%) due to the decrease of endothelial cell count to 936 ± 458 cells/mm2 over 9 years of follow-up. Conclusions: Continuous endothelial cell loss was observed after implantation of angle-supported anterior chamber lens in the long-term follow-up. A constant decline in the endothelial cell density necessitates periodic ophthalmologic evaluation including specular microscopy. J Korean Ophthalmol Soc 2012;53(2):208-214

안구표면질환에서 실리콘 링을 이용한 일시적 양막반의 치료 효과

양재니,심현찬,박대진,Jenny Yang,Hyun Chan Sim,Dae Jin Park 대한안과학회 2012 대한안과학회지 Vol.53 No.1

Purpose: To evaluate the efficacy of the sutureless amniotic membrane (AM) patch for the treatment of ocular surface disorders. Methods: A sutureless AM patch using a silicone ring was utilized to treat neurotrophic ulcer, persistent epithelial defect (PED), Shield ulcer, chemical injury and Stevens-Johnson syndrome. Primary outcome was the time to complete corneal and conjunctival epithelialization. Secondary outcome was the number of repeated insertions and complications of the inserted ring. Results: Neurotrophic ulcer was observed in 4 eyes, PED in 2 eyes, Shield ulcer in 1 eye, chemical injury in 4 eyes and Stevens-Johnson syndrome in 4 eyes. The mean (SD) time to complete epithelialization was 13 (7.2) days (6-20 days) in neurotrophic ulcer, 17.5 (7.7) days (12-23) in PED, 5 days in Shield ulcer, 10.6 (6.6) days (3-15) in chemical injury and 13.5 (0.7) days (13-14) in Stevens-Johnson syndrome. There were no protrusion or mechanical trauma of the inserted ring. In 1 case of neurotrophic ulcer and 1 refractory case of chemical injury, repeated insertion was performed due to incomplete healing after dissolution of the AM. In 2 eyes with Stevens-Johnson syndrome, repeated insertion was necessary with heavy accumulation of inflammatory debris on the AM. No symblepharon or fornix contracture was found in chemical injury or Stevens-Johnson syndrome patients. Conclusions: The sutureless AM patch using a silicone ring was shown to be effective and safe for the treatment of ocular surface disorders. The patch can help surgeons avoid suture-related trauma to the ocular surface during the acute inflammatory period. J Korean Ophthalmol Soc 2012;53(1):27-36

Reduction of train-induced vibrations on adjacent buildings

Hung, Hsiao-Hui,Kuo, Jenny,Yang, Yeong-Bin Techno-Press 2001 Structural Engineering and Mechanics, An Int'l Jou Vol.11 No.5

In this paper, the procedure for deriving an infinite element that is compatible with the quadrilateral Q8 element is first summarized. Enhanced by a self mesh-expansion procedure for generating the impedance matrices of different frequencies for the region extending to infinity, the infinite element is used to simulate the far field of the soil-structure system. The structure considered here is of the box type and the soils are either homogeneous or resting on a bedrock. Using the finite/infinite element approach, a parametric study is conducted to investigate the effect of open and in-filled trenches in reducing the structural vibration caused by a train passing nearby, which is simulated as a harmonic line load. The key parameters that dominate the performance of wave barriers in reducing the structural vibrations are identified. The results presented herein serve as a useful guideline for the design of open and in-filled trenches concerning wave reduction.

Beta-catenin causes fibrotic changes in the ecm via upregulation of collagen I transcription

( Mi Ryung Roh ),( Raj Kumar ),( Apunchelvi Rajadurai ),( Jenny Njauw ),( Kee Yang Chung ),( Hensin Tsao ) 대한피부과학회 2018 대한피부과학회 학술발표대회집 Vol.70 No.2

P200 Beta-catenin causes fibrotic changes in the ECM via upregulation of collagen I transcription

( Mi Ryung Roh ),( Ji Young Choi ),( Raj Kumar ),( Apunchelvi Rajadurai ),( Jenny Njauw ),( Un Hee Ryoo ),( Kee Yang Chung ),( Hensin Tsao ) 대한피부과학회 2016 대한피부과학회 학술발표대회집 Vol.68 No.2

<div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div><div style="display:none">fiogf49gjkf0d</div> Background: Keloid scars represent a pathological response to cutaneous injury. They are characterized by increased proliferation of fibroblasts, especially in the active growth phase, as well as an abnormally increased production of collagen. The Wnt/β-catenin signaling pathway is a multifunctional network that plays an essential role in embryonic development, organogenesis, and tissue homeostasis. Objectives: We hypothesized that expression of stabilized β-catenin in fibroblasts is sufficient to cause fibrotic changes in the ECM via upregulation of collagen I transcription. Methods: First, we identified the expression of β-catenin and collagen in keloid tissues and cell lines. Then, we generated a tetracycline controlled stable immortalized fibroblast cell line expressing β-catenin to explore the role of stabilized β-catenin in collagen I transcription and synthesis. Results: By immunohistochemical staining, fibroblasts in keloid tissues showed significantly higher expression of β -catenin (p=0.046) and collagen I (p=0.002) than those of normal tissues. Immortalized fibroblasts with β-catenin overexpression (IF β-catenin) showed increased β -catenin, collagen I, and collagen III expression. Measurement of mRNA level by RT-PCR showed that β -catenin (p=0.02), col I (p=0.007), and col III (p=0.019) were markedly expressed in IF β-catenin compared to IF control. To determine if β-catenin had a direct transcriptional effect on the collagen I promoter, we generated a COL1A2-luciferase reporter and observed a dose-dependent increase in luciferase activity with increasing amounts of β-catenin. Conclusion: We found that the increased expression of β -catenin in fibroblasts is sufficient for increased collagen I synthesis, with concomitant increases in the COL1A2 luciferase activity. The highly increased levels of β -catenin together with its potent pro-fibrotic effects suggest that β-catenin might be a candidate for anti-fibrotic approaches.

The Accuracy of Transient Elastography and Comparison of Non-invasive Markers for Assessing Fibrosis in Korean Patients with Nonalcoholic Fatty Liver Disease

( Mark Sulkowski ),( Kwang-hyub Han ),( Jia-horng Kao ),( Jenny C. Yang ),( Bing Gao ),( Diana M. Brainard ),( Wan-long Chuang ),( Edward J. Gane ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1

Aims: HBV reactivation during HCV treatment with direct-acting antiviralregimens has been reported in HCV infected patients who areHB surface antigen (HBsAg) negative, HB core antibody (HBcAb) positive,and HBV DNA undetectable. To evaluate the risk of HBV reactivationin these HCV infected patients, we analyzed samples froma Phase 3b study, GS-US-337-0131, of ledipasvir/sofosbuvir (LDV/SOF)for 12 weeks conducted in Korea and Taiwan where HBV is endemic.All enrolled subjects were HBsAg negative at screening per protocol.The SVR12 rate was 98% in this trial.Methods: A serum sample per patient, collected during post-treatmentfollow up was analyzed for HBcAb. Samples positive for HBcAb wereanalyzed for HBV DNA and retested for HBsAg if HBV DNA wasdetectable.Results: 173 of 178 patients had one post-treatment sample withinthe 1 year stability limit. Of the 173 patients, 60% (n=103) wereHBcAb positive and HBsAg negative; no subject was HBsAg positive.Two of 103 patients had HBV DNA <20 IU/mL, detected and theremaining patients were <20 IU/mL, target not detected. MedianALT during treatment and post-treatment follow-up were similar betweenHBcAb positive and negative patients; all patients had ALTdeclined from baseline. No patients had clinical signs of HBV reactivationduring treatment or post-treatment follow up. No differencesin overall adverse events or laboratory abnormality observedin patients who were HBcAb positive or negative.Conclusions: Among 103 HCV-infected patients with reactive HB coreantibody and absent HB surface antigen, there was no evidence ofHBV reactivation following successful HCV treatment with LDV/SOF.These data suggest HBV reactivation in patients with HCV and reactiveHB core antibody is uncommon. A Phase 3b study evaluating 12weeks of LDV/SOF in patients with chronic HCV and overt HBV (HBsAgpositive) co-infection is ongoing in Taiwan and can provide furthersafety information.

Absence of HBV Reactivation among HCV Infected Patients with Reactive Hepatitis B Core Antibody Treated withLedipasvir/Sofosbuvir for 12 Weeks

( Mark Sulkowski ),( Kwang-hyub Han ),( Jia-horng Kao ),( Jenny C. Yang ),( Bing Gao ),( Diana M. Brainard ),( Wan-long Chuang ),( Edward J. Gane ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1

Aims: HBV reactivation during HCV treatment with direct-acting antiviralregimens has been reported in HCV infected patients who areHB surface antigen (HBsAg) negative, HB core antibody (HBcAb) positive,and HBV DNA undetectable. To evaluate the risk of HBV reactivationin these HCV infected patients, we analyzed samples froma Phase 3b study, GS-US-337-0131, of ledipasvir/sofosbuvir (LDV/SOF)for 12 weeks conducted in Korea and Taiwan where HBV is endemic.All enrolled subjects were HBsAg negative at screening per protocol.The SVR12 rate was 98% in this trial.Methods: A serum sample per patient, collected during post-treatmentfollow up was analyzed for HBcAb. Samples positive for HBcAb wereanalyzed for HBV DNA and retested for HBsAg if HBV DNA wasdetectable.Results: 173 of 178 patients had one post-treatment sample withinthe 1 year stability limit. Of the 173 patients, 60% (n=103) wereHBcAb positive and HBsAg negative; no subject was HBsAg positive.Two of 103 patients had HBV DNA <20 IU/mL, detected and theremaining patients were <20 IU/mL, target not detected. MedianALT during treatment and post-treatment follow-up were similar betweenHBcAb positive and negative patients; all patients had ALTdeclined from baseline. No patients had clinical signs of HBV reactivationduring treatment or post-treatment follow up. No differencesin overall adverse events or laboratory abnormality observedin patients who were HBcAb positive or negative.Conclusions: Among 103 HCV-infected patients with reactive HB coreantibody and absent HB surface antigen, there was no evidence ofHBV reactivation following successful HCV treatment with LDV/SOF.These data suggest HBV reactivation in patients with HCV and reactiveHB core antibody is uncommon. A Phase 3b study evaluating 12weeks of LDV/SOF in patients with chronic HCV and overt HBV (HBsAgpositive) co-infection is ongoing in Taiwan and can provide furthersafety information.

All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-infected Patients

Paul Kwo,Alessandra Mangia,Patrick Marcellin,Graham R. Foster,Maria Buti,Norbert Brau,Andrew Muir,Jenny C. Yang,Hongmei Mo,Xiao Ding,Phil S. Pang,William T. Symonds,John G. McHutchison,Stefan Zeuzem,N 한국간담췌외과학회 2014 한국간담췌외과학회 학술대회지 Vol.2014 No.4

Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in CHC and CHB Coinfection Patients: A Phase 3 Study in Taiwan

( Chun-Jen Liu ),( Wan-Long Chuang ),( I-Shyan Sheen ),( Horng-Yuan Wang ),( Chi-Yi Chen ),( Kuo-Chih Tseng ),( Ting-Tsung Chang ),( Benede tta Massetto ),( Jenny Yang ),( Gregory Camus ),( Fangqiu Zh 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: Patients co-infected with HCV and HBV have more rapid progression and worse outcomes than mono-infected patients. Taiwan has among the highest prevalence of chronic HCV/HBV coinfection in Southeast Asia. This study evaluated the safety and efficacy of an all-oral treatment with ledipasvir(LDV)/sofosbuvir(SOF) for 12 weeks in chronic HCV and HBV coinfection. Methods: Patients with or without compensated cirrhosis chronic HCV GT1/GT2 and HBV (HBsAg+) treatment naïve were enrolled into open-label, receiving LDV 90 mg/SOF 400 mg(QD) for 12 weeks. The primary efficacy endpoint is SVR12. HBV DNA was monitored at all study visits and it will be monitored for 2 years post-treatment. Results: A total of 111 patients (68[61%] with GT1 and 43[39%] with GT2) were enrolled and treated. The majority were female(62%), treatment naive(67%), and non-cirrhotic(85%), with a mean age of 55 years and mean BMI of 24.5kg/m2. All but one was HBeAg negative. Mean baseline HBV DNA was 2.1 log10IU/mL. SVR4 was 100%(111/111). The mean change in HBV DNA ranged from -0.06 log10IU/mL at week 1 to +0.49 log10IU/mL at follow-up visit 4; HBV DNA kinetics are shown in Fig 1. 60(54%) patients had an increase in HBV DNA> 10 x BL or became HBV DNA > LLOQ. No patients had ALT ≥ 2 X baseline. No patients discontinued treatment due to adverse events (AEs). Three patients had serious AEs(optic neuritis, post procedural bleeding and duodenal ulcer bleeding; none was considered drug related). Conclusions: In chronic HCV/HBV infection patients, LDV/SOF for 12 weeks resulted in an SVR4 rate of 100%. Although most patients had an increase in HBV DNA during treatment, this was not associated with ALT elevations ≥2 X baseline, and no patients started HBV therapy to date. This all-oral, interferon-free regimen was well tolerated, supporting its potential as a treatment option for HCV/HBV co-infected patients.